Prostate cancer perspectives after chaarted: Optimizing treatment sequence.
Prostate cancer is the most frequent cancer amongst men. Until recently, only two therapeutic options, initial androgen-deprivation therapy in patients without castration-resistant prostate cancer, with addition of docetaxel when the disease becomes castration-resistant, were considered as standard. In the last years, new drugs (abiraterone, enzalutamide, Ra-223, Sipuleucel) have been developed for prostate cancer treatment with important advantages in safety and efficacy. Results from the recent Chaarted study, in patients that received docetaxel for the hormone sensitive disease, have contributed to change the initial treatment approach in metastatic prostate cancer, in order to adapt the best sequence for each patient. Those results have been supported by the Stampede trial. Stampede survival data showed not only a benefit in overall survival of adding docetaxel initially, but also a prolonged time to first skeletal related event. Now it is discussed in which setting the available drugs should be administered. This review article summarizes the treatment options for patients treated with docetaxel initially for hormone sensitive prostate cancer after developing progressive disease, and offers an algorithm proposal for treatment.
Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain. Electronic address: sergio.vazquez.Estevez@sergas.es.
Sergio Vázquez
SV
Estévez
Medical Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela, Spain.
Urbano Anido
UA
Herranz
Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Spain.
Ovidio Fernández
OF
Calvo
Medical Oncology Department, Hospital Arquitecto Marcide de Ferrol, Spain.
Francisco Javier
FJ
Afonso Afonso
Medical Oncology Department, Hospital Povisa de Vigo, Spain.
Lucía Santomé
LS
Couto
Medical Oncology Department, Complexo Hospitalario Universitario de Vigo, Spain.
Martín Lázaro
ML
Quintela
Medical Oncology Department, Servicio Galego de Saúde, Spain.
Luis León
LL
Mateos
Pivotal CRO, Spain. Electronic address: sonia.macia@pivotal.es.
Sonia
S
Maciá Escalante
D000970:Antineoplastic Agents / Q000627:therapeutic use; D020249:Hormone Replacement Therapy; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000628:therapy; D019275:Radiopharmaceuticals / Q000627:therapeutic use
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals
Alpha-emitters; CHAARTED; Docetaxel; Hormonotherapy; Immunotherapy; Prostate cancer